Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 07-Mar-18 6:23 PM View:  | Nelsen Robert Director | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition (change in control) | 50,824 | $87.00 | $4,421,690.00 | (< 1%) 10.6M to 10.55M | |
| 07-Mar-18 6:16 PM View: | Cassidy Bernard J General Counsel & Secretary | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition (change in control) | 5,558 | $87.00 | $483,546.00 | (17%) 32.43K to 26.87K | |
| 07-Mar-18 6:24 PM View: | Pien Howard H Director | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition (change in control) | 111,587 | $87.00 | $9,708,070.00 | (100%) 111.59K to 0 | |
| 07-Mar-18 6:20 PM View: | Harr Steve CFO & Head, Corp. Development | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition | 147,162 | $29.57 | $4,350,870.00 | (23%) 639.52K to 492.36K | |
| 07-Mar-18 6:15 PM View: | Bishop Hans Edgar CEO & President Director | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition | 184,281 | $23.05 | $4,248,120.00 | (8%) 2.45M to 2.26M | |
| 07-Mar-18 6:14 PM View: | Barron Hal Director | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition (change in control) | 100,000 | $87.00 | $8,700,000.00 | (100%) 100.0K to 0 | |
| 07-Mar-18 6:13 PM View: | Azelby Robert EVP & Chief Commercial Officer | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition | 89,612 | -- | -- | (100%) 89.61K to 0 | |
| 07-Mar-18 6:23 PM View: | Nelsen Robert Director | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition (change in control) | 10,552,400 | $87.00 | $918,057,984.00 | (100%) 10.55M to 0 | |
| 07-Mar-18 6:22 PM View: | Lee Ann L. EVP, Technical Operations | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition | 110,792 | -- | -- | (100%) 110.79K to 0 | |
| 07-Mar-18 6:16 PM View: | Cassidy Bernard J General Counsel & Secretary | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition (change in control) | 26,869 | $87.00 | $2,337,600.00 | (100%) 26.87K to 0 | |
| 07-Mar-18 6:15 PM View: | Bishop Hans Edgar CEO & President Director | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition (change in control) | 2,263,950 | $87.00 | $196,963,008.00 | (100%) 2.26M to 0 | |
| 07-Mar-18 6:11 PM View: | Agarwal Sunil President of R & D | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition | 149,577 | -- | -- | (100%) 149.58K to 0 | |
| 07-Mar-18 6:21 PM View: | Klausner Richard Director | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition (change in control) | 705,525 | $87.00 | $61,380,700.00 | (100%) 705.52K to 0 | |
| 07-Mar-18 6:14 PM View: | Barron Hal Director | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition | 3,780 | $87.00 | $328,860.00 | (4%) 103.78K to 100.0K | |
| 07-Mar-18 6:20 PM View: | Harr Steve CFO & Head, Corp. Development | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition (change in control) | 492,355 | $87.00 | $42,834,900.00 | (100%) 492.36K to 0 | |
| 07-Mar-18 6:19 PM View: | Flatley Jay T Director | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition (change in control) | 31,500 | $87.00 | $2,740,500.00 | (100%) 31.5K to 0 | |
| 07-Mar-18 6:23 PM View: | Nelsen Robert Director | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition | 3,234 | $87.00 | $281,358.00 | (< 1%) 10.61M to 10.6M | |
| 07-Mar-18 6:16 PM View: | Cassidy Bernard J General Counsel & Secretary | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition | 79,825 | -- | -- | (71%) 112.25K to 32.43K | |
| 07-Mar-18 6:24 PM View: | Pien Howard H Director | Juno Therapeutics, Inc. (JUNO) | 05-Mar-18 | Disposition | 5,050 | $87.00 | $439,350.00 | (4%) 116.64K to 111.59K | |
| 01-Mar-18 6:23 PM View: | Harr Steve CFO & Head, Corp. Development | Juno Therapeutics, Inc. (JUNO) | 27-Feb-18 | Grant | 11,544 | -- | -- | 2% 627.97K to 639.52K | |
| 07-Mar-18 6:18 PM View: | Evnin Anthony B Director | Juno Therapeutics, Inc. (JUNO) | 14-Feb-18 | Gift | 34,842 | -- | -- | (100%) 34.84K to 0 | |
| 07-Mar-18 6:24 PM View: | Pien Howard H Director | Juno Therapeutics, Inc. (JUNO) | 13-Feb-18 | Gift | 1,162 | -- | -- | (< 1%) 117.8K to 116.64K | |
| 14-Feb-18 7:24 PM View: | Azelby Robert EVP & Chief Commercial Officer | Juno Therapeutics, Inc. (JUNO) | 12-Feb-18 | Market Sale (Planned) | 4,157 | $85.55 | $355,631.00 | (4%) 93.77K to 89.61K | |
| 07-Mar-18 6:18 PM View: | Evnin Anthony B Director | Juno Therapeutics, Inc. (JUNO) | 09-Feb-18 | Gift | 25,000 | -- | -- | (42%) 59.84K to 34.84K | |
| 07-Mar-18 6:24 PM View: | Pien Howard H Director | Juno Therapeutics, Inc. (JUNO) | 09-Feb-18 | Gift | 12,251 | -- | -- | (9%) 130.05K to 117.8K | |
| 09-Feb-18 7:27 PM View: | Azelby Robert EVP & Chief Commercial Officer | Juno Therapeutics, Inc. (JUNO) | 08-Feb-18 | Market Option Sale (Planned) | 3,497 | $85.77 | $299,938.00 | (4%) 97.27K to 93.77K | |
| 09-Feb-18 7:27 PM View: | Azelby Robert EVP & Chief Commercial Officer | Juno Therapeutics, Inc. (JUNO) | 08-Feb-18 | Option Exercise | 3,497 | $21.84 | $76,375.70 | 4% 93.77K to 97.27K | |
| 09-Feb-18 7:32 PM View: | Harr Steve CFO & Head, Corp. Development | Juno Therapeutics, Inc. (JUNO) | 07-Feb-18 | Gift | 162,790 | -- | -- | (21%) 790.76K to 627.97K | |
| 09-Feb-18 7:29 PM View: | Bishop Hans Edgar CEO & President Director | Juno Therapeutics, Inc. (JUNO) | 07-Feb-18 | Gift | 116,280 | -- | -- | (5%) 2.56M to 2.45M | |
| 09-Feb-18 7:27 PM View: | Azelby Robert EVP & Chief Commercial Officer | Juno Therapeutics, Inc. (JUNO) | 07-Feb-18 | Payment of Exercise | 2,700 | $85.49 | $230,823.00 | (3%) 96.47K to 93.77K | |
| 09-Feb-18 7:31 PM View: | Cassidy Bernard J General Counsel & Secretary | Juno Therapeutics, Inc. (JUNO) | 07-Feb-18 | Payment of Exercise | 1,528 | $85.49 | $130,629.00 | (1%) 140.29K to 138.76K | |
| 07-Mar-18 6:21 PM View: | Klausner Richard Director | Juno Therapeutics, Inc. (JUNO) | 07-Feb-18 | Gift | 23,250 | -- | -- | (3%) 728.77K to 705.52K | |
| 09-Feb-18 7:31 PM View: | Cassidy Bernard J General Counsel & Secretary | Juno Therapeutics, Inc. (JUNO) | 07-Feb-18 | Gift | 26,634 | -- | -- | (19%) 138.76K to 112.13K | |
| 09-Feb-18 7:32 PM View: | Harr Steve CFO & Head, Corp. Development | Juno Therapeutics, Inc. (JUNO) | 07-Feb-18 | Payment of Exercise | 1,704 | $85.49 | $145,675.00 | (< 1%) 792.47K to 790.76K | |
| 09-Feb-18 7:29 PM View: | Bishop Hans Edgar CEO & President Director | Juno Therapeutics, Inc. (JUNO) | 07-Feb-18 | Payment of Exercise | 4,346 | $85.49 | $371,540.00 | (< 1%) 2.57M to 2.56M | |
| 02-Feb-18 7:26 PM View: | Azelby Robert EVP & Chief Commercial Officer | Juno Therapeutics, Inc. (JUNO) | 01-Feb-18 | Option Exercise | 4,167 | $51.76 | $215,684.00 | 4% 96.47K to 100.64K | |
| 02-Feb-18 7:26 PM View: | Azelby Robert EVP & Chief Commercial Officer | Juno Therapeutics, Inc. (JUNO) | 01-Feb-18 | Market Option Sale (Planned) | 4,167 | $85.78 | $357,445.00 | (4%) 100.64K to 96.47K | |
| 02-Feb-18 7:26 PM View: | Azelby Robert EVP & Chief Commercial Officer | Juno Therapeutics, Inc. (JUNO) | 31-Jan-18 | Grant | 25,639 | -- | -- | 36% 70.83K to 96.47K | |
| 02-Feb-18 7:33 PM View: | Lee Ann L. EVP, Technical Operations | Juno Therapeutics, Inc. (JUNO) | 31-Jan-18 | Grant | 40,788 | -- | -- | 58% 70.0K to 110.79K | |
| 02-Feb-18 7:25 PM View: | Agarwal Sunil President of R & D | Juno Therapeutics, Inc. (JUNO) | 31-Jan-18 | Grant | 29,135 | -- | -- | 24% 120.44K to 149.58K | |
| 02-Feb-18 7:29 PM View: | Cassidy Bernard J General Counsel & Secretary | Juno Therapeutics, Inc. (JUNO) | 31-Jan-18 | Grant | 25,639 | -- | -- | 22% 114.65K to 140.29K | |
| 02-Feb-18 7:31 PM View: | Harr Steve CFO & Head, Corp. Development | Juno Therapeutics, Inc. (JUNO) | 31-Jan-18 | Grant | 29,135 | -- | -- | 4% 763.33K to 792.47K | |
| 02-Feb-18 7:28 PM View: | Bishop Hans Edgar CEO & President Director | Juno Therapeutics, Inc. (JUNO) | 31-Jan-18 | Grant | 66,426 | -- | -- | 3% 2.5M to 2.57M | |
| 24-Jan-18 6:46 PM View: | Azelby Robert EVP & Chief Commercial Officer | Juno Therapeutics, Inc. (JUNO) | 22-Jan-18 | Option Exercise | 102,539 | $51.76 | $5,307,420.00 | 145% 70.83K to 173.37K | |
| 24-Jan-18 6:46 PM View: | Azelby Robert EVP & Chief Commercial Officer | Juno Therapeutics, Inc. (JUNO) | 22-Jan-18 | Market Option Sale (Planned) | 102,539 | $86.25 | $8,843,990.00 | (59%) 173.37K to 70.83K | |
| 19-Jan-18 9:00 PM View: | Azelby Robert EVP & Chief Commercial Officer | Juno Therapeutics, Inc. (JUNO) | 17-Jan-18 | Option Exercise | 29,131 | $21.15 | $616,076.00 | 41% 70.83K to 99.96K | |
| 19-Jan-18 9:00 PM View: | Azelby Robert EVP & Chief Commercial Officer | Juno Therapeutics, Inc. (JUNO) | 17-Jan-18 | Market Option Sale (Planned) | 29,131 | $68.61 | $1,998,600.00 | (29%) 99.96K to 70.83K | |
| 18-Jan-18 9:30 PM View: | Bishop Hans Edgar CEO & President Director | Juno Therapeutics, Inc. (JUNO) | 16-Jan-18 | Option Exercise | 245,750 | $6.36 | $1,562,970.00 | 10% 2.53M to 2.77M | |
| 18-Jan-18 9:30 PM View: | Bishop Hans Edgar CEO & President Director | Juno Therapeutics, Inc. (JUNO) | 16-Jan-18 | Market Sale | 24,500 | $46.17 | $1,131,260.00 | (< 1%) 2.53M to 2.5M | |
| 18-Jan-18 9:30 PM View: | Bishop Hans Edgar CEO & President Director | Juno Therapeutics, Inc. (JUNO) | 16-Jan-18 | Market Option Sale | 245,750 | $46.17 | $11,347,300.00 | (9%) 2.77M to 2.53M |
